hotspot -WSS

hotspot

author：fashion 2025-08-08 08:10:13 - browse：645

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Large hospital system sues Multiplan for low

Wikipedia

WSS

GOP presidential candidates start declaring their loyalty

AI for drug discovery: Experts on separating hype from reality

Where are patients getting their prescriptions for GLP

Brain technologies pose threats that are all too real, experts warn

Crowdfunding for medical bills sidesteps core problem, author says

TB outbreak tied to bone grafts underscores testing shortcomings

focus

hotspot

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

Faced with fears of OxyContin misuse, sales reps touted its safety

Walensky prepares to leave CDC — and Congress — behind

Brain MRIs reveal impact of 'toxic stress' on Black children

Psychedelics group wrestles with new pharma identity

Class action alleges UnitedHealth concealed DOJ probe

Alkermes shareholders re

Timeline: Special counsel's investigation into Trump's handling of classified documents

Novavax promises a turnaround & Lilly roils the obesity market

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

focus

TB outbreak tied to bone grafts underscores testing shortcomings

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

Has Bernie Sanders reached the limit of his pharma bullying effort?

GSK’s asthma push continues as drug succeeds in Phase 3 trials

White House drug shortages task force keeps mum with Congress

focus

focus

Wikipedia

entertainment